PLUS THERAPEUTICS, Inc.

Please stand by. Your program is about to begin. If you need audio assistance during today's program, please press star zero. Good afternoon, ladies and gentlemen. Welcome to the PLUS Therapeutics first quarter 2022 results call. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. If you would like to ask a question at that time, please press star one on your touch-tone telephone keypad. If at any point your question has been answered, you may remove yourself from the queue by pressing the pound key. We ask that you please pick up your handset to allow optimal sound quality. If you should require operator assistance, please press star zero. Before we begin, we want to advise you that over the course of the call and question and answer session, forward-looking statements will be made regarding events, trends, business prospects, and financial performance, which may affect Plus Therapeutics' future operating results and financial position. All such statements are subject to risk and uncertainties, including the risk and uncertainties described under the risk factors section included in Plus Therapeutics' annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission from time to time. Plus Therapeutics advises you to review these risk factors in considering such statements. Plus Therapeutics assumes no responsibility to update or revise any forward-looking statements to reflect events, trends, or circumstances after the date they are made. It is now my pleasure to turn the floor over to Dr. Mark Hedrick, Plus Therapeutics President and Chief Executive Officer. Sir, you may begin.

Thank you very much, Gretchen. Good afternoon, everyone. Thank you once again for taking the time to join us today as we provide an overview of recent business highlights and discuss our 2022 first quarter financial results. Joining me on the call today is Dr. Norman LaFrance, our Chief Medical Officer, and Andrew Sims, our Chief Financial Officer. I'll begin the call by reviewing our recent corporate and clinical progress before turning the call over to Norman who will provide commentary on our clinical progress for 2022. And then following, Norm and Andrew will review our financials. Despite the short interval since we last reported quarterly results, I continue to be very pleased with our overall progress as we work towards several meaningful catalysts and milestones throughout 2022. During the first quarter, we began enrolling patients in our Respect LM trial of 186 RNL in patients with leptomeningeal metastases, or LM. The trial is a multicenter 1-2A dose escalation study to determine the MTD, maximum tolerated dose, and MFD, and safety and efficacy of RNL 186 in LM. LM is a typically fatal complication associated with advanced cancers that affect the fluid line structures of the central nervous system, or leptomeninges. Median survival with current aggressive treatment is about three to eight and a half months, depending on which primary tumor caused the LM.

And the one and two- Survival without treatment is only a few weeks.